Overview
- AbbVie, which reported Wednesday, posted adjusted earnings of $2.65 per share on $15 billion in revenue, beating forecasts and lifting shares about 2% to 3% in premarket trading.
- Sales of Skyrizi rose 30.9% to $4.48 billion and Rinvoq rose 23.3% to $2.12 billion, driving gains in the immunology business.
- Neuroscience revenue increased 26% to $2.88 billion, and Botox Therapeutic topped $1 billion in a single quarter for the first time.
- Humira revenue fell 38.6% to $688 million as lower-cost biosimilars continued to take market share after its 2023 U.S. patent loss.
- AbbVie raised its 2026 adjusted EPS outlook to $14.08 to $14.28, and GAAP earnings dropped to $0.39 per share in part from $0.41 of acquired R&D and milestone costs recorded through the quarter.